Italia markets open in 1 hour 15 minutes
  • Reuters

    GLOBAL MARKETS-Stocks hit by tech slide; yen flails at intervention zone

    Asian stocks fell on Thursday as disappointing earnings forecasts from Facebook parent Meta Platforms hammered tech shares, while the yen's slump past 155 per dollar for the first time since 1990 raised the spectre of intervention from Tokyo. A 15% dive in shares of Meta in extended trading after the Instagram parent forecast lighter-than-expected current quarter revenue and higher expenses soured the mood, sparking a sell-off in U.S. tech and tech-related stocks. The hit to Asian tech stocks took MSCI's broadest index of Asia-Pacific shares outside Japan down 0.5%.

  • Reuters

    PRESS DIGEST- New York Times business news - April 25

    Changpeng Zhao, the founder of the giant cryptocurrency exchange Binance, should go to prison for three years after breaking the law "on an unprecedented scale" and pleading guilty to a money-laundering violation, federal prosecutors wrote in a court filing on Wednesday. - A group of seven leading solar manufacturers filed trade complaints with the Department of Commerce and the U.S. International Trade Commission on Wednesday formally requesting that the Biden administration impose tariffs on solar products being exported from Southeast Asia into the United States. - The Food and Drug Administration on Wednesday approved the sale of an antibiotic, Pivmecillinam for the treatment of urinary tract infections in women, giving U.S. health providers a powerful new tool to combat a common infection that is increasingly unresponsive to the existing suite of antimicrobial drugs.

  • PR Newswire

    Sedana Medical completes patient recruitment for INSPiRE-ICU 1 clinical trial in the US

    Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States. Concurrently, the identical INSPiRE-ICU 2 trial is nearing completion, with 23 of 235 randomized patients remaining. The company anticipates topline results from both trials in the second half of 2024, with a planned New Drug Application (NDA) submission in the first quarter of 2025.